| Trial ID: | L3374 |
| Source ID: | NCT01403025
|
| Associated Drug: |
Liraglutide
|
| Title: |
Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: liraglutide
|
| Outcome Measures: |
Primary: The incidence of SADRs (Serious Adverse Drug Reactions), After 36 months | Secondary: The incidence rate and type of SAEs (Serious Adverse Events), At month 1, 3, 6, 12, 24 and 36|The incidence rate and type of ADRs (Adverse Drug Reactions), At month 1, 3, 6, 12, 24 and 36
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
4121
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2011-07-19
|
| Completion Date: |
2015-12-28
|
| Results First Posted: |
|
| Last Update Posted: |
2018-02-12
|
| Locations: |
Novo Nordisk Investigational Site, Tokyo, 1000005, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT01403025
|
